PR99021

HYDERABAD, India, Nov. 29, 2022 /PRNewswire＝KYODO JBN/ --

    Latest study shows Sanzyme Biologics's Bacillus coagulans SNZ

1969(R)(Weizmannia coagulans SNZ 1969), a natural spore forming probiotic

strain over five decades of use and more than 30 human studies across age

groups found to be effective in managing IBS symptoms. This study is unique as

it covers both the IBS-Diarrhea and IBS-Constipation groups with larger number

of subjects.

    Irritable bowel syndrome (IBS) is one of the most common disorders of

gut-brain interaction, estimated to affect around 11% people globally. The

outcome of this study will be significant to supplement manufacturers as it can

help design products to address consumer need for managing IBS symptoms with a

scientifically studied probiotic strain. Several factors, such as the

increasing fear of antibiotic resistance, the increasing demand of consumers

for natural substitutes for drugs, and the emergence of scientific and clinical

evidence showing the efficacy of probiotics, have contributed to many health

professionals considering probiotics as an alternative to drug remedies.

    In a randomized, double blind, placebo-controlled study, probiotic

potential of SNZ 1969(R) has been studied in subjects with constipation

predominant irritable bowel syndrome (IBS-C) and diarrhea predominant irritable

bowel syndrome (IBS-D). Significant reduction in GSRS IBS score was seen in

both the treatment group compared to placebo (P <0.0001). SNZ 1969® was

well-tolerated and showed significant alleviation of IBS-associated clinical

symptoms compared to placebo and improved the Quality of Life of IBS patients

    This study was conducted at Apollo Hospitals, Hyderabad, India and

published in the International Journal of Basic & Clinical Pharmacology.

https://www.ijbcp.com/index.php/ijbcp/article/view/5120

    The same strain has been studied earlier for gastrointestinal discomfort,

intestinal motility and intermittent constipation among healthy subjects. GI

discomfort study showed an improvement in total SODA scores, including specific

symptoms such as burping/belching, bloating, heartburn, passing gas, nausea,

bad breath, and sour taste compared with placebo. Intestinal motility study

concluded that SNZ 1969(R) reaches the colon intact and ameliorates intestinal

motility and gut microbiota composition.

    Sanzyme Biologics was incorporated in 1969 as Uni-Sankyo. Over the last

five decades Sanzyme Biologics established its strength in probiotics by

developing scientifically studied and well-documented probiotic strains,

pioneered their applications beyond human health into aqua, veterinary, poultry

and bioremediation. Sanzyme Biologics has market presence in over 40 countries.

    To know more, visit https://www.sanzymebiologics.com/ or contact

info@sanzymebiologics.com. Ph: +91-40-48589999

    Photo: https://mma.prnewswire.com/media/1956162/SNZ_1969.jpg

    Logo: https://mma.prnewswire.com/media/1956163/Sanzyme_Logo.jpg

    Source: Sanzyme Biologics